Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMELEON: Avutometinib, Defactinib, and Letrozole in Upfront Low-Grade Serous Ovarian Cancer
NCT06394804Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avutometinib, defactinib in Low grade serous ovarian cancer (LGSOC), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2024; status: recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
Low grade serous ovarian cancer (LGSOC)
Beyond the preview
Go deeper on NCT06394804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394804.